Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials LK Shankar, JM Hoffman, S Bacharach, MM Graham, J Karp, ... Journal of Nuclear Medicine 47 (6), 1059-1066, 2006 | 815 | 2006 |
Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin FS Hodi, CL Corless, A Giobbie-Hurder, JA Fletcher, M Zhu, ... Journal of clinical oncology 31 (26), 3182-3190, 2013 | 687 | 2013 |
PET/CT today and tomorrow DW Townsend, JPJ Carney, JT Yap, NC Hall Journal of Nuclear Medicine 45 (1 suppl), 4S-14S, 2004 | 613 | 2004 |
Bevacizumab plus ipilimumab in patients with metastatic melanoma FS Hodi, D Lawrence, C Lezcano, X Wu, J Zhou, T Sasada, W Zeng, ... Cancer immunology research 2 (7), 632-642, 2014 | 565 | 2014 |
Protective autophagy elicited by RAF→ MEK→ ERK inhibition suggests a treatment strategy for RAS-driven cancers CG Kinsey, SA Camolotto, AM Boespflug, KP Guillen, M Foth, A Truong, ... Nature medicine 25 (4), 620-627, 2019 | 564 | 2019 |
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas S George, P Merriam, RG Maki, AD Van den Abbeele, JT Yap, T Akhurst, ... Journal of Clinical Oncology 27 (19), 3154-3160, 2009 | 369 | 2009 |
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma JP Leonard, AS LaCasce, MR Smith, A Noy, LR Chirieac, SJ Rodig, ... Blood, The Journal of the American Society of Hematology 119 (20), 4597-4607, 2012 | 344 | 2012 |
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial S George, Q Wang, MC Heinrich, CL Corless, M Zhu, JE Butrynski, ... Journal of Clinical Oncology 30 (19), 2401-2407, 2012 | 290 | 2012 |
New response evaluation criteria in solid tumors (RECIST) guidelines for advanced non–small cell lung cancer: comparison with original RECIST and impact on assessment of tumor … M Nishino, DM Jackman, H Hatabu, BY Yeap, LA Cioffredi, JT Yap, ... American journal of roentgenology 195 (3), W221-W228, 2010 | 276 | 2010 |
Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET PA Kaufmann, T Gnecchi-Ruscone, JT Yap, O Rimoldi, PG Camici Journal of nuclear medicine 40 (11), 1848-1856, 1999 | 271 | 1999 |
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate HL Anderson, JT Yap, MP Miller, A Robbins, T Jones, PM Price Journal of Clinical Oncology 21 (15), 2823-2830, 2003 | 250 | 2003 |
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2 … IA Mayer, VG Abramson, SJ Isakoff, A Forero, JM Balko, MG Kuba, ... Journal of clinical oncology 32 (12), 1202-1209, 2014 | 196 | 2014 |
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw N Raje, SB Woo, K Hande, JT Yap, PG Richardson, S Vallet, N Treister, ... Clinical Cancer Research 14 (8), 2387-2395, 2008 | 165 | 2008 |
Intensity modulated radiation therapy: a clinical perspective AJ Mundt, JC Roeske PMPH-USA, 2005 | 165 | 2005 |
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine … E Ben-Ami, CM Barysauskas, M Von Mehren, MC Heinrich, CL Corless, ... Annals of Oncology 27 (9), 1794-1799, 2016 | 123 | 2016 |
Performance evaluation of the microPET®—FOCUS-F120 R Laforest, D Longford, S Siegel, DF Newport, J Yap IEEE Transactions on Nuclear Science 54 (1), 42-49, 2007 | 120 | 2007 |
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular … KM Krajewski, M Guo, AD Van den Abbeele, J Yap, N Ramaiya, ... European urology 59 (5), 856-862, 2011 | 116 | 2011 |
F18-fluorodeoxyglucose–positron emission tomography/computed tomography screening in li-Fraumeni syndrome S Masciari, AD Van den Abbeele, LR Diller, I Rastarhuyeva, J Yap, ... Jama 299 (11), 1315-1319, 2008 | 114 | 2008 |
Image-guided cancer therapy using PET/CT JT Yap, JPJ Carney, NC Hall, DW Townsend The Cancer Journal 10 (4), 221-233, 2004 | 111 | 2004 |
Summary of the UPICT protocol for 18F-FDG PET/CT imaging in oncology clinical trials MM Graham, RL Wahl, JM Hoffman, JT Yap, JJ Sunderland, R Boellaard, ... Journal of Nuclear Medicine 56 (6), 955-961, 2015 | 110 | 2015 |